Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral administration. By blocking the aromatase enzyme, it lowers peripheral estrogen synthesis and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant product sourced from the European Union market, providing reliable access to oncology centres, hospitals and pharmacies worldwide through its international distribution network and ensuring compliance with local regulatory requirements.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive early‑stage breast cancer: improves disease‑free survival as adjuvant therapy in postmenopausal women. - Hormone receptor‑positive metastatic breast cancer: reduces tumor progression and extends overall survival in postmenopausal patients. - Hormone receptor‑positive locally advanced breast cancer: used to shrink tumors before surgery or radiation in postmenopausal women.

Adverse reactions may occur with letrozole therapy.

Common Side Effects: - Hot flashes - Joint and muscle pain - Nausea or vomiting - Fatigue

Serious or Rare Side Effects: - Severe liver dysfunction - Pulmonary embolism or deep‑vein thrombosis - Bone fractures due to decreased bone mineral density

Before initiating letrozole, consider the following precautions. - Monitor bone health: assess bone mineral density periodically. - Evaluate liver function: perform baseline and periodic liver enzyme tests. - Assess cardiovascular risk: watch for signs of thrombosis or hypertension. - Review concomitant medications: avoid strong CYP2C19 inhibitors that may increase exposure. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Letrozole may interact with other medicines; review the following.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: combined use may reduce efficacy of both agents.

Moderate Interactions (Monitor Closely): - CYP2C19 substrates (e.g., clopidogrel): may have altered metabolism. - Anticoagulants (e.g., warfarin): monitor INR as letrozole may affect clotting risk. - Antidepressants (e.g., SSRIs): observe for additive fatigue or dizziness.